BioAI and Genomic Testing Cooperative Announce Strategic Collaboration to Provide AI-Powered Digital Pathology Solutions for Clinical Research and Diagnostic Applications

BioAI and Genomic Testing Cooperative Announce Strategic Collaboration to Provide AI-Powered Digital Pathology Solutions for Clinical Research and Diagnostic Applications


Manchester, NH – June 25, 2024 – BioAI, an emerging biotech company applying multimodal artificial intelligence (AI) to novel biomarker discovery, development, and diagnostics, announced a strategic collaboration with Genomic Testing Cooperative (GTC), a leading provider of molecular diagnostics for solid tumors and hematologic malignancies. This collaboration leverages the AI capabilities of both companies to deliver innovative solutions that meet the needs of pharmaceutical companies and clinicians, ultimately enhancing patient care in oncology.  GTC will become an early technology access member of BioAI’s global ecosystem of clinical laboratories.   

Goals of the collaboration include: 

  • Data Access and AI Training: GTC will provide BioAI with access to characterized imaging data to train AI algorithms for product development and sponsored projects. 
  • Biomarker Development: Joint efforts will focus on developing genomic biomarker screening algorithms and assays, deploying them in clinical settings. 
  • Comprehensive Solutions: Customers will benefit from a suite of solutions encompassing screening tests and comprehensive genomic profiling using DNA and RNA for tissue and liquid biopsies. 

Thomas Colarusso, CEO of BioAI, stated: 
“BioAI is excited to partner with leaders in clinical laboratory services and diagnostics such as GTC to support the development, validation and future deployment of novel AI-based tests. GTC is a perfect partner for us since they have a strong track record of developing and launching new clinical biomarker tests for primary care and supporting biopharma research and clinical trials to improve patient care and drive therapy decisions.” 

Jeff Owen, Vice President, Marketing, stated: “GTC is delighted to partner with  BioAI, their digital pathology technology strengthens our product portfolio to pharmaceutical clients and will help us to demonstrate the potential of our digital and molecular sample bank in the development of clinically useful comprehensive biomarkers. 
We recognize that AI algorithms in digital pathology when combined with molecular profiling advance our capability of developing biomarkers that can be used by all pathologists.”  

About BioAI 

BioAI is a leading provider of multimodal AI for digital health in precision medicine, offering world-leading machine learning technology to develop digital biomarkers and H&E based predictive models. They partner with leading pharmaceutical, biotechnology, clinical laboratories, and academic cancer centers around the world. With the PredictX Platform, BioAI aims to revolutionize personalized medicine by improving drug efficacy and patient outcomes. 
For more information about BioAI and its innovative machine learning technologies, visit

About Genomic Testing Cooperative, LCA  

Genomic Testing Cooperative (GTC) is a privately-owned molecular testing company located in Lake Forest, CA. The company operates based on a cooperative (co-op) business model.  Members of the co-op hold type A shares with voting rights. The company offers its patron members a full suite of comprehensive genomic profiling based mainly on next generation sequencing.  Molecular alterations are identified based on rigorous testing with the aid of specially developed algorithms to increase accuracy and efficiency. The clinical relevance of the detected alterations is pulled from numerous databases using internally developed software. Relevance of findings to diagnosis, prognosis, selecting therapy, and predicting outcome are reported to members. The co-op model allows GTC to make the testing and information platform available to members at a lower cost because of a lower overhead. For more information, please visit  

Forward Looking Statements  

All the statements, expectations and assumptions in this press release are forward-looking. Such forward-looking statements are based on the GTC management’s current expectations and include statements regarding the value of comprehensive genomic profiling, RNA profiling, DNA profiling, algorithms, therapy, the ability of testing to provide clinically useful information. All information in this press release is as of the date of the release, and GTC undertakes no duty to update this information unless required by law.  

Media Contacts

Ashlyn Alese 
Director of Marketing 

Jeff Owen 
VP, Marketing 
Genomic Testing Cooperative 


Τumor-informed vs Tumor-naïve

Liquid biopsies are a rapidly evolving diagnostic technology with numerous labs offering commercially available tests today. Most labs have taken an approach of cell-free (cfDNA) (also called circulating tumor DNA,

Read More »

Subscribe to our Newsletter

Get all the critical news and events sent straight to your inbox

Share this post with your friends